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Background: Pulmonary emphysema is characterized by irreversible airflow obstruction, inflammation, oxidative
stress imbalance and lung remodeling, resulting in reduced lung function and a lower quality of life. Flavonoids are
plant compounds with potential anti-inflammatory and antioxidant effects that have been used in folk medicine.
Our aim was to determine whether treatment with sakuranetin, a flavonoid extracted from the aerial parts of
Baccharis retusa, interferes with the development of lung emphysema.
Methods: Intranasal saline or elastase was administered to mice; the animals were then treated with sakuranetin or
vehicle 2 h later and again on days 7, 14 and 28. We evaluated lung function and the inflammatory profile in
bronchoalveolar lavage fluid (BALF). The lungs were removed to evaluate alveolar enlargement, extracellular matrix
fibers and the expression of MMP-9, MMP-12, TIMP-1, 8-iso-PGF-2α and p65-NF-κB in the fixed tissues as well as to
evaluate cytokine levels and p65-NF-κB protein expression.
Results: In the elastase-treated animals, sakuranetin treatment reduced the alveolar enlargement, collagen and
elastic fiber deposition and the number of MMP-9- and MMP-12-positive cells but increased TIMP-1 expression. In
addition, sakuranetin treatment decreased the inflammation and the levels of TNF-α, IL-1β and M-CSF in the BALF
as well as the levels of NF-κB and 8-iso-PGF-2α in the lungs of the elastase-treated animals. However, this treatment
did not affect the changes in lung function.
Conclusion: These data emphasize the importance of oxidative stress and metalloproteinase imbalance in the
development of emphysema and suggest that sakuranetin is a potent candidate that should be further investigated
as an emphysema treatment. This compound may be useful for counteracting lung remodeling and oxidative stress
and thus attenuating the development of emphysema.
Keywords: Emphysema, Flavonoid, NF-κB, Oxidative stress, Lung remodeling, Experimental models* Correspondence: carla.prado@unifesp.br
1Department of Biological Science, Universidade Federal de São Paulo, Rua
Artur Riedel, 275 - Eldorado, Diadema, SP, Brazil
3Department of Medicine, Faculdade de Medicina da Universidade de São
Paulo, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2015 Taguchi et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Taguchi et al. Respiratory Research  (2015) 16:79 Page 2 of 15Background
The main feature of chronic obstructive pulmonary disease
(COPD) is pulmonary airflow restriction that is not fully
reversible; this limitation is usually progressive and is asso-
ciated with an abnormal inflammatory response to the in-
halation of noxious particles and gases. COPD is usually
initiated by exposure to aggressive agents, such as cigarette
smoke, which induce secretory gland hypertrophy and
hyperplasia as well as mucus hypersecretion; these are
characteristics of chronic bronchitis, a component of
COPD [1]. In the periphery, chronic airway inflammation
induces a repetitive process of injury and repair, leading to
structural alterations in airways. Three states of COPD
have been well described; these states can occur concomi-
tantly or separately and include narrowed airway thick-
ness, limited expiratory airflow, and increased production
of secretions, which induces chronic cough and emphy-
sema. Indeed, it is difficult to differentiate between chronic
bronchitis and emphysema because they often coexist in
COPD [1].
Emphysema, which develops in 15 % to 20 % of
smokers and 1 % of non-smokers [2], is defined as an
airspace enlargement that is usually induced by oxidative
stress and an imbalance between proteases and antipro-
teases that leads to inflammatory processes. In turn, a
sequential cascade of responses is triggered that culmin-
ate in tissue destruction [3]. Several proinflammatory cy-
tokines and chemokines, such as tumor necrosis factor
(TNF)-α, interleukin (IL)-1β, macrophage inflammatory
protein (MIP)-2 and monocyte chemoattractant protein
(MCP)-1, as well as certain growth factors such as
macrophage colony-stimulating factor (M-CSF), are in-
volved in COPD physiopathology and contribute to main-
taining the inflammation [2]. The transcription factor
nuclear factor-kappa B (NF-κB) controls the expression of
many of the inflammatory and apoptotic genes present in
COPD [4].
Macrophages and neutrophils release matrix metallopro-
teases (MMPs), which are proteolytic enzymes, and tissue
inhibitors of metalloproteinases (TIMPs). In emphysema,
the expression of MMP-9 and MMP-12 is increased [5].
Destruction and repair of the lung parenchyma occur to-
gether in emphysema, and the observed destruction could
be, at least in part, a consequence of misguided repair. The
turnover of extracellular matrix fibers is continuous and
results from the migration and persistence of inflamma-
tory cells recruited by the protease/antiprotease imbalance
and oxidative stress.
Reactive oxygen species (ROS) and nitrogen species
are involved in the development of COPD. It is well
known that, in COPD, there is not only an increase in
oxidants production but also an important reduction in
the anti-oxidative potential since the levels of some anti-
oxidant can be significantly diminished [6, 7]. Antioxidantsingested through the diet and supplements can remove
ROS and provide health benefits [8]. Many studies have
shown that vegetables are rich sources of antioxidant com-
pounds, such as phenols, flavonoids, quinones, and vita-
mins, that may decrease the incidence of diseases
associated with oxidative stress [9, 10].
Flavonoids, which are low molecular weight aromatic
compounds with up to 15 carbon atoms in the basic
skeleton, are natural pigments found in many plants
[8, 11] and are widely consumed. Some of these com-
pounds can be found in specimens of the Baccharis
genus, which is represented by more than 500 species
distributed primarily in the tropical areas of South
America, including Brazil. Many of these species are ex-
tensively used in folk medicine for the treatment or pre-
vention of anemia, diabetes, stomach and liver diseases,
and inflammation [12]. Several different flavonoids have
been described in these species [13], including sakuranetin
(5,4’-dihydroxy-7-methoxyflavanone), which was previ-
ously reported to be the main component of the aerial
parts of B. retusa [14]. Our group recently showed that
sakuranetin has potential in vitro antileishmanial and anti-
trypanosomal activity [15] as well as anti-inflammatory
activity in an in vivo experimental asthma model [16].
Currently, the recommended treatment for COPD in-
volves controlling the symptoms, reducing exacerbations
and improving the quality of life, but these interventions
do not reverse lung emphysema or even prevent disease
progression [17]. Sakuranetin is a potential antioxidant
because it is a flavanone with reported anti-inflamma-
tory activity. We therefore hypothesized that sakuranetin
would interfere with emphysema physiopathology.
To investigate the anti-inflammatory and antioxidant
effects of flavonoids in emphysema, we used an experi-
mental model of emphysema. In this model, emphysema
is induced via the instillation of elastase into C57BL6
mice. The present study showed reductions in lung in-
flammation, which was associated with attenuated lung
parenchymal remodeling, and in alveolar destruction in
the sakuranetin-treated emphysematous animals. These
effects appeared to be mediated through the inhibition
of NF-κB. Our findings highlight the importance of
counteracting oxidative stress and metalloproteinase ac-
tivity in the physiopathology of emphysema and provide
insights into a new therapeutic modality for treating em-
physema, lung inflammation and oxidative stress in
cases that are not controlled by conventional treatments.
Methods
Ethics statement
This study was approved by the Ethics Committees of
UNIFESP (CEP; protocol number 0982/10) and USP
(CAPPESQ; protocol number 307/10). All the animals
received humane care according to the "Guide for the
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Laboratory Animal Resources - 1996), and all the surgi-
cal procedures were performed while the animals were
under general anesthesia. The mice used in this study
were maintained in a temperature-controlled room at
21–23 °C with a 12-hour light/dark cycle and ad libitum
access to water and food.
Baccharis retusa collection and extraction/isolation of
sakuranetin
The aerial portions of Baccharis retusa DC. were col-
lected in Campos do Jordão/SP, Brazil, in October 2011.
The plant material was identified by Dr. Oriana A. Fávero
and compared with a voucher specimen (SPSF44897) de-
posited at the Herbario D. Bento Pickel, Instituto Florestal
de São Paulo (IF/SP), São Paulo, Brazil.
Powdered, air-dried aerial parts of B. retusa (500 g) were
defatted with hexane (4 X 500 mL) and exhaustively ex-
tracted with MeOH at room temperature. After partial re-
moval of the solvent, the extract was resuspended in
MeOH:H2O (1:2 v/v) and extracted successively with hex-
ane, CH2Cl2, and EtOAc. The CH2Cl2 phase was subjected
to column chromatography over silica gel (230–400 mesh;
Merck, Kenilworth, NJ, USA) and eluted with CH2Cl2 con-
taining increasing amounts of EtOAc (up to 100 %) to pro-
duce six fractions (A1–A6). Fraction A2 (712 mg)
contained pure sakuranetin, which was analyzed by nu-
clear magnetic resonance (NMR; 1H and 13C) and low-
resolution electronic impact mass spectrometry (LREIMS)
(see Additional file 1).
Experimental groups
A total of 30 C57BL6 male mice aged 7–9 weeks and
weighing 25 g were randomly assigned to one of 4
groups: a, saline and sakuranetin (SAL+SK group, n = 7);
b, elastase and sakuranetin (ELA+SK group, n = 8); c, sa-
line and DMSO vehicle (SAL+Ve group, n = 7); and d,
elastase and DMSO vehicle (ELA+Ve group, n = 8). An-
other set of 30 animals were assigned to the groups de-
scribed above (values of n were the same as described
above) and were treated similarly; these animals were
used only for evaluating lung mechanics, after which the
lungs were removed and frozen. At the end of the proto-
col, the animals were 11 to 13 weeks old. DMSO was
used to dilute sakuranetin because it is insoluble in pure
saline.
Protocol for elastase-induced emphysema
The animals were anesthetized with an intramuscular in-
jection of ketamine (40 mg/kg) and xylazine (5 mg/kg)
before the infusion of porcine pancreatic elastase (PPE)
(day zero). The ELA+SK and ELA+Ve groups received
50 μL of elastase (6.6 units/mg, E1250, Type 1; Sigma,
St. Louis, MO) via an intranasal drop (0.677 IU) [18].The animals in the SAL+SK and SAL+Ve groups
received an intranasal instillation of the same volume of
saline.
Protocol for sakuranetin treatment
The animals in the SAL+SK and ELA+SK groups were
treated with sakuranetin by intranasal instillation on day
0 (2 h after the instillation of saline or elastase) and on
days 7, 14 and 28 of the experimental protocol. The dose
of 20 mg/kg diluted in 10 μL of DMSO:saline (1:4) was
selected based on previous studies that used this com-
pound in other experimental models [16]. The control
animals (SAL+Ve and ELA+VE groups) were treated
with vehicle via the same method.
Respiratory mechanics evaluation
Thirty minutes after the last sakuranetin treatment and
28 days after the elastase instillation, the animals were
deeply anesthetized with an intraperitoneal injection of
thiopental (70 mg/kg), tracheotomized and then con-
nected to a small animal ventilator (FlexiVent, SCIREQ,
Montreal, Canada). The animals were ventilated at 150
breaths/min with a tidal volume of 10 mL/kg, and a
positive end expiratory pressure (PEEP) of 5 cm H2O
was applied. Vcyl was corrected to obtain the actual vol-
ume in the animals (V), and Pcyl was corrected based
on the value of Pao (open airway pressure). We obtained
the flow (V') by the derivation of V with respect to time.
We analyzed the respiratory system resistance (Rrs) and
elastance (Ers) as previously described [16]. The experi-
mental data from the forced oscillation technique were
obtained only after the animals had been paralyzed with
pancuronium bromide (0.2 mg/kg). Oscillatory lung me-
chanics were analyzed by producing flow oscillations at
different frequencies (from 0.25 to 19.625 Hz) for 16 s.
The pressure and flow data were obtained, and the air-
way impedance was calculated at each frequency. Airway
resistance [19], tissue damping (Gtis) and tissue elas-
tance (Htis) parameters were obtained by applying the
constant phase model [20].
Bronchoalveolar lavage fluid (BALF)
At the end of the mechanical evaluation, the anterior
chest wall was opened, the animals were exsanguinated
via the abdominal aorta, and the BALF was collected
[16]. The trachea was cannulated, and the BALF was ob-
tained by washing the airway lumen with 0.5 mL of ster-
ile saline and withdrawing the fluid. This procedure was
repeated three times. The recovered volume was greater
than 95 % of the instilled fluid, and the fluid was trans-
ferred to a test tube on ice. For total and differential cell
counting, the BALF was centrifuged (Model GS-6R Cen-
trifuge, Beckman Instruments, Fullerton, USA) at 800 x
g for 8 min at 5 °C, and the cell pellet was resuspended
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cells was determined using a Neubauer hemocytometer
and an optical microscope (Model BX40 Olympus
Optical Co. Tokyo, Japan) at 400X magnification. Differ-
ential cell counting was performed on cytocentrifuge
preparations of BALF (450 rpm for 6 min) (model:
Cytospin 3, Shandon Instruments, Sewickley, USA) on
glass slides, which were stained with Diff-Quick (Bio-
chemical Sciences Inc., Swedesboro, NJ). At least 300
cells were differentiated according to the standard mor-
phologic criteria at a magnification of 1000X using the
optical microscope described above.Morphometric studies
After collecting the BALF, the lungs were removed in
blocks, fixed using 4 % buffered formalin infused
through the trachea at a constant pressure of 20 cm
H2O for 24 h (to maintain a similar alveolar histoarchi-
tecture among the groups), and embedded in paraffin.
Histological sections (3–5 μm thickness) were cut and
subjected to morphometric analysis.Mean linear intercept (Lm)
Lung tissue sections from five animals per group were
stained with hematoxylin and eosin (H&E) to evaluate
the mean linear intercept, an index that is widely used
to characterize the presence of emphysema [18]. For this
analysis, an eyepiece with a coherent system of 50 lines,
100 points, and a known area was attached to the micro-
scope ocular (Model BX40 Olympus Co). The mean lin-
ear intercept (Lm) was assessed in 20 randomly selected,
non-overlapping fields of the distal lung parenchyma in
each animal at a magnification of 200X, and we counted
the number of times that the lines of the integrating eye-
piece intersected with the alveolar septum.Extracellular matrix (ECM) remodeling
Picrosirius (Direct Red 80, CI 35780; Sigma Aldrich,
Milwaukee, WI) was used to quantify collagen fibers,
and Weigert’s resorcin-fuchsin with oxidation was used
to detect elastic fibers. A Leica DM4000B microscope
(Leica Microsystems, Wetzlar, Germany), a digital cam-
era (Leica DFC420 Leica Microsystems) and Image-Pro
Plus 4.5 image analysis software (Image-Pro Plus for
Windows 98/NT/2000 4.5.0.29, Media Cybernetics Inc.,
Bethesda, MD, USA) were used to evaluate collagen and
elastic fiber deposition in the alveolar walls. Ten ran-
domly selected fields from each animal were evaluated
at 400X magnification. The collagen and elastic fiber
area was expressed as a percentage of the total alveolar
wall area [16].Immunohistochemistry
Immunohistochemical staining was performed with an
antibody against the isoprostane 8-iso-PGF2α (1:10,000
dilution; Oxford Biomedical Research, Rochester Hills,
MI) [16] as an indirect method to evaluate oxidative
stress. The sections were deparaffinized and washed
seven times for 5 min with 3 % H2O2 to inhibit en-
dogenous peroxidase activity. After the PBS and water
washes, antigen retrieval was performed with trypsin for
20 min. Then, the sections were washed in PBS three
times for 3 min each and incubated overnight with the
anti-8-iso-PGF2α antibody diluted in BSA. After the sec-
tions were washed with PBS, the reagent from the Vec-
tastain ABC Kit (Vector Elite PK-6105, Burlingame,
USA) was used as the secondary antibody, and DAB
(Sigma-Aldrich) was used as the chromogen. The sections
were counterstained with Harris hematoxylin (Merck,
Darmstadt, Germany). The image analysis of the 8-iso-
PGF-2α-stained slides was performed as described previ-
ously [16]. The 8-iso-PGF-2α-positive area in the lung was
expressed as a percentage of the total area of the lung
tissue.
Detection of cells positive for MMP-9, MMP-12, TIMP-1
and p65-NF-κB
Immunohistochemical staining was performed using
goat polyclonal IgG anti-MMP-9 (SC6840, 1:500 dilu-
tion), goat polyclonal IgG anti-MMP-12 (SC8839,
1:1.200 dilution), rabbit polyclonal IgG anti-TIMP-1 (SC
5538, 1:100 dilution), and rabbit polyclonal IgG anti-
p65-NF-κB (SC109, 1:300 dilution) antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) using the same
biotin–streptavidin–peroxidase method described above.
We determined the number of cells positive for MMP-9,
MMP-12, TIMP-1 and p65-NF-κB using the point-
counting technique as described above. Twenty ran-
domly selected fields of the alveolar wall were analyzed
in each animal at 1000X magnification. The results are
expressed as the number of positive cells per unit area
(104 μm2) [16].
Bio-Plex
The lungs were removed and quickly frozen to obtain
cytokine measurements in the lung homogenate. A Bio-
Plex Mouse Cytokine Assay Kit (Bio-Rad Laboratories,
Inc., Hercules, CA, USA) was used to determine the
presence of 5 cytokines in the lung homogenates. The
assay was performed using the Bio-Plex suspension array
system, and the data were analyzed using Bio-Plex Man-
ager software version 4.0. The standard curves ranged
from 32,000 to 1.95 pg/mL, as previously described [16].
The values for M-CSF, TNF-α, IL-1β, MCP-1 and MIP-2
in the lung homogenates were expressed as pg cytokine/
mg total protein.
Taguchi et al. Respiratory Research  (2015) 16:79 Page 5 of 15p65-NF-κB protein analysis by Western blotting
Lung fragments weighing approximately 100 mg were ho-
mogenized in a boiling extraction buffer [10 % SDS,
100 mM Tris (pH 7.4), 10 mM EDTA, 10 mM sodium
pyrophosphate, 100 mM sodium fluoride, and 10 mM so-
dium vanadate] with a Polytron PTA 20S generator (model
PT 10/35, Brinkmann Instruments, Inc., Westbury, NY) at
maximum speed for 30 s. The extracts were centrifuged at
15,000 x g for 15 min at 4 °C to remove the insoluble ma-
terial. The protein concentrations in the supernatants were
determined using the Bradford assay, and an equal amount
of total protein from each sample (75 μg) was treated with
Laemmli buffer containing 100 mM dithiothreitol. The
samples were heated in a boiling water bath for 5 min and
then subjected to SDS-PAGE (10 % bis-acrylamide).
The proteins were electrotransferred from the gel to a
nitrocellulose membrane over 90 min at 120 V (con-
stant) as described previously [21]. Nonspecific protein
binding to nitrocellulose was reduced by preincubating
the membrane overnight at 4 °C in blocking buffer
(2.5 % milk/TBST). The nitrocellulose membrane was
then incubated overnight at 4 °C with anti-p65-NF-κB
(1:400; Santa Cruz Biotechnology, Santa Cruz, CA) and
anti-β-actin (1:1000; Sigma Aldrich, St. Louis, MO) anti-
bodies diluted in blocking buffer and washed for 30 min
with TBST.
The bound antibodies were detected with horserad-
ish peroxidase-conjugated (HRP-conjugated) anti-IgG
(1:10,000) and visualized using chemiluminescence
with UVItec (UVItec Limited, Cambridge, UK). The
band intensities were quantified using the UVItec
Image Program.
Statistical analysis
The data were analyzed using Sigma Stat 10 (SPSS Inc.,
CA, USA). Normality was evaluated using the Kolmogorov-
Smirnov test, and the data are presented as the mean ± SE.
The parametric data were analyzed by two-way ANOVA
(with elastase treatment and sakuranetin treatment as the
two parameters) followed by the Holm-Sidak test. Differ-
ences with p < 0.05 were considered significant.
Results
Chemical characterization of sakuranetin
The isolated flavonoid was characterized based on analysis
by NMR (1H and 13C) and LREIMS (see Additional file 1).
The spectroscopic data were compared with those re-
ported in the literature [16] to confirm the identification
of sakuranetin (5,4′-dihydroxy-7-methoxyflavanone).
Vehicle treatment (DMSO plus saline) did not affect lung
responses
Because DMSO is an organo-sulfur compound that pos-
sesses both toxic and antioxidant effects, we firstevaluated whether DMSO treatment (vehicle) interfered
with lung inflammation and 8-iso-PGF-2α expression by
comparing vehicle-treated animals (DMSO+Saline) with
untreated animals. There were no significant differences
in lung inflammation or in the 8-iso-PGF-2α-positive
area (evaluated by t-test) between animals treated with
or without vehicle (see Additional file 1). Therefore, we
used the vehicle-treated animals as controls for sakuranetin
treatment. We previously evaluated the effects of DMSO
in other models of lung disease and did not observe any
effects [16].Sakuranetin treatment did not affect lung elastance
The Ers and Htis values are presented in Fig. 1 (a and b,
respectively). The ELA+Ve group exhibited lower Ers
values compared with the SAL+Ve group (p < 0.05).
Sakuranetin treatment had no effect on Ers compared
with the vehicle-treated elastase-instilled animals since
ELA+SK showed; similar results than SAL+Ve and ELA
+Ve groups. We observed a reduction in Htis (Fig. 1b)
in the ELA+Ve group compared with the control groups
(SAL+Ve and SAL+SK) (p < 0.05). Sakuranetin treatment
had no effect on Htis in the elastase-treated groups.
There were no significant differences in the Rrs, Gtis
and Raw values among the experimental groups (data
not shown).Sakuranetin treatment reduced lung inflammation and
pro-inflammatory cytokine levels in lung homogenates
In Fig. 1c-g, we present the number of total cells (c),
macrophages (d), lymphocytes (e), neutrophils (f ) and
eosinophils (g). The animals that received elastase and
were treated with vehicle (ELA+Ve) or sakuranetin (ELA
+SK) showed an increase in total cell number and in the
number of macrophages, neutrophils and lymphocytes
compared with the control groups (p < 0.001 for all com-
parisons). The number of total cells, macrophages, lym-
phocytes and neutrophils was reduced in the elastase-
instilled animals treated with sakuranetin (ELA+SK)
compared with the elastase-instilled, vehicle-treated ani-
mals (p < 0.05). There were no differences in the number
of eosinophils among the experimental groups (Fig. 1g).
The cytokine concentrations in the lung homogenates
(pg of cytokine/mg of total protein) were measured
using the Bio-Plex system (Table 1). The ELA group had
higher levels of M-CSF, IL-1β and TNF-α compared with
the control groups (p < 0.05). In addition, sakuranetin
treatment reduced the levels of these cytokines (p <
0.01). Although there was a tendency (p = 0.08) for in-
creased MCP-1 expression in the ELA+Ve group, there
were no significant differences in MIP-2 and MCP-1
levels among the experimental groups.
Fig. 1 Lung mechanics and lung inflammation. The mean and standard error (SE) of respiratory system elastance (Ers) a and lung tissue elastance
(Htis) b evaluated using a Flexivent ventilator under anesthesia 28 days after elastase or saline instillation. After the lung mechanics were
evaluated, the animals were exsanguinated, and bronchoalveolar lavage fluid was collected. We quantified total cells c, macrophages d,
lymphocytes e, neutrophils f and eosinophils g in the four groups. SAL+Ve: control group with vehicle treatment; ELA+Ve: elastase instillation and
vehicle treatment; SAL + SK: control group treated with sakuranetin; ELA+SK: elastase- and sakuranetin-treated group. *p < 0.05 compared with the
control (SAL+Ve and SAL+SK); **p < 0.05 compared with the ELA+Ve group
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Lm was evaluated as an indicator of lung tissue destruc-
tion. The Lm values in the four experimental groups are
presented in Fig. 2a. Lm increased in the animals that
received elastase and vehicle (ELA+Ve) compared with
the animals that received saline and vehicle (SAL+Ve)
(p < 0.001). Sakuranetin treatment attenuated the em-
physema, as indicated by the lower Lm in the ELA+SK
group compared with the elastase-instilled, vehicle-
treated group (p < 0.001). Sakuranetin treatment had no
effect in the control groups. Photomicrographs of lung
tissue from representative animals from the SAL+Ve (b),
ELA+Ve (c) and ELA+SK (d) groups are presented in
Fig. 2 (Fig. 2b-d). We observed intense alveolar destruc-
tion associated with the presence of inflammatory cells
in the ELA+Ve group (arrows, Fig. 2c). These responses
were diminished in the elastase-instilled, sakuranetin-
treated animals (arrows, Fig. 2c).Sakuranetin treatment reduced alveolar remodeling by
interfering with the metalloprotease and TIMP balance
The quantification of collagen (e) and elastic (f ) fibers in
the lung parenchyma is shown in Fig. 2e-l. There were
more collagen and elastic fibers in the lung parenchyma
from the elastase-instilled, vehicle-treated animals (ELA
+Ve) compared with the lung parenchyma from the con-
trol animals (SAL+Ve and SAL+SK) (p < 0.001 for all
comparisons). Sakuranetin treatment reduced both colla-
gen (p < 0.05) and elastic (p < 0.01) fiber deposition in elas-
tase-treated animals (ELA+SK vs ELA+Ve; p < 0.05).
Figure 2g-l presents representative photomicrographs
of lung tissue from animals in the SAL+Ve (g and j),
ELA+Ve (h and k) and ELA+SK (i and l) groups that
was stained for collagen (g-i) or elastic (j-l) fibers. We
observed increased collagen and elastic fiber deposition
in the ELA+Ve animals (arrows, Fig. 2h and k). This re-
sponse was attenuated by sakuranetin treatment (arrows,
Fig. 2i and l).Table 1 Effects of sakuranetin treatment on cytokine release in
lung homogenates as quantified by ELISA (Bio-Plex)
SAL+Ve ELA+Ve SAL+SK ELA+SK
M-CSF (pg/mL) 1.08 ± 1.05 10.95 ± 1.36* 1.64 ± 1.37 1.72 ± 1.18**
IL-1β (pg/mL) 0.92 ± 0.18 1.92 ± 0.25* 1.28 ± 0.25 0.82 ± 0.22**
MCP-1 (pg/mL) 5.90 ± 2.32 11.00 ± 2.32 4.73 ± 2.68 8.77 ± 2.32
TNFα (pg/mL) 0.21 ± 0.03 0.33 ± 0.04* 0.15 ± 0.04 0.15 ± 0.03**
MIP-2 (pg/mL) 10.00 ± 1.50 10.24 ± 1.50 7.98 ± 1.93 10.55 ± 1.50
Data are presented as the mean ± SE. SAL+Ve: control group with vehicle
treatment; ELA+Ve: elastase instillation and vehicle treatment; SAL+SK: control
group treated with sakuranetin; ELA + SK: elastase- and sakuranetin-treated
group. *p < 0.05 compared with the SAL groups; **p < 0.01 compared with the
ELA+Ve groupBecause the degradation and turnover of collagen and
elastic fibers are controlled by the balance between
MMPs and TIMPs, we used immunohistochemistry to
analyze the expression of TIMP-1, MMP-9 and MMP-12
(Fig. 3). We observed an increase in the number of cells
that were positive for MMP-9, MMP-12 and TIMP-1 in
the ELA+Ve group compared with the control groups
(SAL+Ve and SAL+SK) (p < 0.001 for all comparisons).
Sakuranetin treatment reduced the number of MMP-9-
and MMP-12-positive cells in the elastase-treated ani-
mals compared with the vehicle-treated animals (p <
0.001), although the number of MMP-9-positive cells
was also higher compared with control (p < 0.001). In
addition, sakuranetin treatment increased the number of
TIMP-1-positive cells in the ELA+SK animals compared
with the ELA+Ve animals (p < 0.001). There were no dif-
ferences in any of these parameters between the control
groups.
Figure 3d-l presents photomicrographs of lung tissue
immunostained for TIMP-1 (d-f ), MMP-9 (g-i) and
MMP-12 (j-l) from the SAL+Ve (d, g and j), ELA+Ve (e,
h and k) and ELA+SK (f, i and l) groups.
Sakuranetin treatment reduced oxidative stress,
measured as 8-iso-PGF-2α, in lung tissue
In Fig. 4a-d, we observed an increase in the 8-iso-PGF-
2α-positive area in vehicle-treated animals that received
elastase (ELA+Ve) compared with the saline control ani-
mals (p < 0.001). Treating the elastase-instilled animals
with sakuranetin (ELA+SK) reduced the 8-iso-PGF-2α-
positive area compared with the ELA+Ve group (p <
0.001). There were no significant differences in oxidative
stress between the control groups.
Figure 4d-d presents photomicrographs of 8-iso-PGF-
2α-stained lung tissue from the SAL+Ve (b), ELA+Ve
(c) and ELA+SK (d) groups. We observed an obvious in-
crease in the 8-iso-PGF-2α-positive area in the alveolar
septa of the elastase-instilled animals (c) compared with
the saline-instilled animals (b). Sakuranetin treatment
markedly reduced the positive staining (arrows, Fig. 4d).
Sakuranetin treatment reduced the number of NF-κB-positive
cells in lung tissue and NF-κB protein expression
We quantified the NF-κB-positive cells in lung tissue
(Fig. 5a-d) by immunohistochemistry and determined
the NF-κB protein content in lung homogenates by
Western blotting (Fig. 5e-f ). NF-κB expression, as exam-
ined by immunostaining and Western blotting, was
higher in the animals that received elastase (ELA+Ve)
compared with those that received saline (SAL+Ve) (p <
0.05). Treating the elastase-instilled animals with sakura-
netin reduced both the number of NF-κB-positive cells
and the NF-κB content (ELA+SK vs ELA+Ve; p < 0.05).
Treatment with sakuranetin did not affect NF-κB
Fig. 2 Mean alveolar diameter (Lm) and pulmonary remodeling. The data are presented as the mean and SE for the four groups. The Lm a,
which correlates with alveolar destruction, was increased in the ELA+Ve group c compared with the control group b. Sakuranetin treatment
attenuated this response in ELA+SK animals d. Pulmonary remodeling was characterized by collagen e and elastic f fiber content in the alveolar
septum. There was increased deposition of collagen and elastic fibers in the alveolar septum in the animals that received elastase (collagen h and
elastic k fibers). Sakuranetin treatment (ELA+SK) attenuated this response (collagen i and elastic l fibers) and generated values that were similar to
those in the control group g represent collagen and j elastic fibers). Collagen and elastic fibers are indicated by arrows. *p < 0.001 compared with
the SAL+Ve group; **p < 0.001 (A) and **p < 0.05 (E) compared with the ELA+Ve group
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the lung tissue immunostained for NF-κB are shown in
Fig. 5b-d. Intense positive staining was observed in theanimals that received elastase (c), and this positive stain-
ing was reduced by sakuranetin treatment (d). A repre-
sentative blot is shown in Fig. 5f.
Fig. 3 Expression of MMP-9, MMP-12 and TIMP-1 in lung tissue. The mean and SE of the number of cells in the lung parenchyma that were positive
for TIMP-1 a, MMP-9 b and MMP-12 c. Representative photomicrographs of lung parenchyma immunostained for TIMP-1 d-f, MMP-9 g-i and MMP-12
j-l. The number of positive cells for TIMP-1, MMP-9 and MMP-12 increased in animals that received elastase e, h and k compared with control animals
d, g and j. Interestingly, sakuranetin increased the number of TIMP-1-positive cells and reduced the number of MMP-9- and MMP-12-positive cells in
the elastase-treated groups f, i and l; see arrows). *p < 0.001 compared with the SAL+Ve and SAL+SK groups; **p < 0.05 compared with the
ELA+Ve group
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In the present study, we evaluated whether sakuranetin
derived from the plant Baccharis retusa interferes with
the inflammatory changes and destruction of lung tissue
that is observed in an experimental murine emphysema
model generated by the intranasal instillation of elastase.
We showed that treatment with sakuranetin 2 h after
elastase instillation attenuated lung inflammation,
alveolar destruction and lung remodeling characterized
by collagen and elastic fiber deposition. Furthermore,
sakuranetin improved the imbalance between theexpression of metalloproteinases (MMP-9 and MMP-12)
and TIMP-1. One possible mechanism for sakuranetin
activity could involve the regulation of NF-κB activation;
sakuranetin decreased the expression of certain pro-in-
flammatory cytokines, including M-CSF, IL-1β and
TNF-α, and regulated oxidative stress.
The animals that received elastase presented with
emphysema, lung inflammation, increased collagen and
elastic fiber deposition in the lung parenchyma and
oxidative stress; these data confirm those from a
previous study [18].
Fig. 4 Oxidative stress in lung tissue. 8-iso-PGF-2α-positive area (mean and SE) within the lung parenchyma a. Representative photomicrographs of the
lung parenchyma immunostained for 8-iso-PGF-2α b-d. Vehicle-treated animals that received elastase showed an increase in the 8-iso-PGF-2α-positive
area c compared with animals in the control group b. This response was attenuated in elastase-treated animals that received sakuranetin treatment d
compared with the ELA+Ve animals c. Arrows represent the isoprostane-positive area. *p < 0.001 compared with the SAL+Ve group; **p < 0.001
compared with the ELA+Ve group
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[14–16] and shown to be the main component of the
species Baccharis retusa (Asteraceae), a plant that is
found in large quantities in southern Brazil. The dose of
sakuranetin chosen in the present study was based on a
previous report from our laboratory [16] and data from
other in vivo models in which a dose–response curve
was determined. In the current study, mice were treated
with sakuranetin two hours after elastase instillation on
day 0 and then again on days 7, 14 and 28. No adverse
clinical effects were observed in the animals that re-
ceived this treatment.
Corticosteroids are currently the principal treatment
for COPD patients, particularly because both chronic
bronchitis and emphysema are associated with lung in-
flammation. This class of drugs reduces at least some of
the lung inflammation. However, little or no effect on
lung destruction has been observed [17, 22]. Because
lung destruction is the most important feature of em-
physema, drugs that interfere with these alterations are
relevant. In this study, we observed a reduction in alveo-
lar destruction, as evidenced by the Lm index, in animals
that received elastase and were treated with sakuranetin.
This result suggests that this treatment may protect the
lung against alveolar destruction, which is an important
feature of emphysema. Although sakuranetin was admin-
istered 2 h after the elastase instillation, which does not
simulate a treatment approach, Munoz-Barrutia et al. [23]used micro-CT chest imaging and pulmonary function
tests to show enlargement of the airspaces within 1 h of
elastase instillation.
Pulmonary inflammation is associated with the patho-
genesis of COPD. The sakuranetin-treated animals had
fewer total cells, macrophages, lymphocytes, and neutro-
phils in the BALF. Mainly, sakuranetin had an effect on
the number of macrophages: 95 % of the cells in the
BALF were macrophages. Consistent with our findings,
other studies using elastase models have observed that
approximately 95 % of the cells in the BALF were mac-
rophages [18]. In addition, sakuranetin reduced the
levels of M-CSF, which is correlated with the effects on
macrophages [24]. Although neutrophils are central to
the pathophysiology of COPD, the number of neutro-
phils in the BALF was quite low in the present study.
Nevertheless, sakuranetin treatment reduced the number
of neutrophils. Neutrophilic inflammation usually occurs
after elastase instillation and is resolved after the first
week [18, 25]. The time point evaluated in the present
study (28 days) most likely explains the low number of
neutrophils in the BALF.
Our data suggest that sakuranetin had an important
anti-inflammatory effect in this model. However, al-
though sakuranetin reduced lung inflammation by 50 %,
the number of inflammatory cells was higher in the elas-
tase- and sakuranetin-treated animals than in the non-
emphysematous animals. Higher doses of sakuranetin or
Fig. 5 NF-κB in lung tissue. NF-κB-positive area (mean and SE) in the lung parenchyma a. Representative photomicrographs of the lung parenchyma
immunostained for NF-κB b-d. Vehicle-treated animals that received elastase showed an increase in the NF-κB-positive area c compared with animals in
the control group b. This response was attenuated in elastase animals by sakuranetin treatment d; compared with the ELA+Ve group c. NF-kB protein
content and a representative Western blot of NF-kB e-f. The Western blot corroborates the immunohistochemistry data. *p < 0.05 compared with the
SAL+Ve group; **p < 0.05 compared with the ELA+Ve group
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could produce more significant anti-inflammatory effects
and should be the subject of future studies.
The anti-inflammatory effects of flavonoids have been
shown in other models, and these effects most likely in-
volve reducing the levels of pro-inflammatory cytokines
and chemotactic factors and suppressing oxidative stress.According to Vlahos et al. [22], M-CSF is responsible for
regulating the number of leukocytes during COPD patho-
genesis. Kersul et al. [24] showed that the levels of IL-8,
IL-6, IL-1β and TNF-α in sputum increase during emphy-
sema exacerbation in humans. We showed that sakuranetin
treatment reduced M-CSF, IL-1β and TNF-α levels, sug-
gesting a regulatory effect on inflammatory cytokine levels.
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late NF-κB activation, which in turn controls pro-inflam-
matory cytokine release, as suggested by Song et al. [26].
We previously showed that the effect of sakuranetin
on allergic inflammation could also be due to effects on
NF-κB regulation [16]. In the present study, sakuranetin
potentially acted as an anti-inflammatory compound by
inhibiting the expression of p65-NF-κB; sakuranetin
treatment reduced both the number of NF-κB-positive
cells in the lung parenchyma and NF-κB protein expres-
sion in the lung homogenates from the elastase-instilled
animals. Importantly, the p65, c-REL, and RER-B sub-
units each possess a C-terminal transactivation domain;
therefore, dimers of these aforementioned subunits are
necessary to activate NF-κB gene transcription [27, 28],
suggesting that sakuranetin attenuated the activation of
p65-NF-κB.
Few studies have evaluated the effects of flavonoids in
COPD. In this regard, Bras et al. [29] showed that poly-
phenolic compounds inhibit the activity of elastase. Culpitt
et al. [30] showed that resveratrol, a component of red
wine, reduces cytokine production by macrophages iso-
lated from patients with COPD. Consistent with our re-
sults, Lixuan et al. [31] showed that baicalin reduces
inflammation by inhibiting NF-κB in a cigarette smoke-
induced model. There are no previous studies of sakurane-
tin in emphysema models.
Nevertheless, in terms of the effects on macrophages,
sakuranetin did not reduce the levels of MCP-1 or MIP-
2. These chemokines possess chemotactic properties that
are important for the proliferation, differentiation and
survival of lymphocytes, monocytes and basophils and
participate in the activation and the late responses of
neutrophils and monocytes [32].
Morphological changes in the collagen and elastic
fibers are features of the pathophysiology of emphysema.
Although lung remodeling associated with COPD has
been studied for some years, it remains controversial,
and the alterations in the lung structure of patients with
emphysema have not been fully elucidated [33]. Struc-
tural changes in the ECM, including significant changes
in the collagen, elastin and proteoglycan content, occur
during the development of emphysema both in humans
[33] and in experimental rodent models of this disease
[18, 34]. It is known that the lung repair process may
occur in a disorganized manner in individuals with em-
physema [35, 33], and this feature contributes to the ir-
reversible deterioration of lung function [34, 35].
Black et al. [5] demonstrated a reduction of approxi-
mately 18 % in elastic fibers in the lung parenchyma in
emphysematous patients with various degrees of obstruc-
tion. Vlahovic et al. [36] studied lung biopsies from pa-
tients with emphysema and showed that the levels of
collagen and elastic fibers were increased by approximately3- or 4-fold compared with lungs from non-emphysema-
tous patients. However, Spears et al. [37] observed a similar
collagen content in lung strips from patients with COPD
and in control subjects.
In our experimental model, there were increases in
both collagen and elastic fibers 28 days after the elastase
treatment. Similarly increased levels of elastic fibers in
elastase-treated animals have been observed in other ex-
perimental models [18, 38]. It is possible, however, that
this increase in elastic fibers is associated with the turn-
over of elastic fibers that are destroyed by the elastase
instillation. We measured the total elastic fiber content
without considering the structure of these fibers. Abnor-
mal structure may be associated with the functional de-
terioration of these fibers, which can directly affect lung
function. In this study, sakuranetin prevented the lung
remodeling process in animals treated with elastase, as
indicated by a reduction in the amount of collagen and
elastic fibers in the alveolar septae.
The processes of ECM repair and degradation are
known to be largely controlled by MMPs and their in-
hibitors. The expression of MMPs, particularly MMP-1,
MMP-2, MMP-9 and MMP-12, is increased in patients
with COPD [5], and this increase contributes to ECM
degradation and the subsequent repair and turnover of
fibers. Some authors have suggested that MMP-9 and
MMP-12 are relevant to emphysema, are involved in
experimental models of elastase [39], and are involved in
the degradation of collagen fibers. The evaluation of MMP-
9, MMP-12 and TIMP-1 expression in the inflammatory
cells in the lung parenchyma revealed that sakuranetin re-
duced the number of MMP-9- and MMP-12-positive cells
in emphysematous animals. MMP activity is regulated by
TIMPs [40]. Therefore, we also assessed the expression of
TIMP-1 in cells within lung tissue. Treatment with sakura-
netin increased the number of TIMP-1-positive cells. This
effect may be responsible for the reduction in MMP-9 and
MMP-12 expression that was observed in the ELA+SK ani-
mals. Consistent with our findings, Ganesan et al. [41]
showed that in mice with elastase/LPS-induced emphy-
sema, quercetin treatment reduced MMP-9 and MMP-12
activity and increased the expression of SIRT-1, which reg-
ulates MMP expression. Together, these results suggest that
sakuranetin regulates the remodeling process in this model
primarily by modulating the balance between MMPs and
TIMPs.
Increases in ROS levels and/or decreases in antioxi-
dant levels induce oxidative stress. The response to oxi-
dative stress is the major mechanism implicated in the
development of pulmonary emphysema and is involved
in the recruitment of inflammatory cells and the de-
struction of alveolar tissue [3]. To assess whether the ef-
fects of sakuranetin in this model were due to a
reduction in oxidative stress, we evaluated the levels of
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stress that is produced at the end of the oxidative reac-
tion [42]. Sakuranetin reduced the 8-iso-PGF-2α-positive
area, suggesting that the effects of sakuranetin in this ex-
perimental model can be at least partly attributed to its
antioxidant activity. However, these data did not indicate
whether the effects of sakuranetin involved reducing oxi-
dants and/or increasing antioxidant substances. In agree-
ment with our results, others have demonstrated that
polyphenolic compounds can directly reduce oxidative
stress in vitro and in vivo [11, 26].
Notably, we treated the animals with sakuranetin two
hours after the elastase instillation. With respect to the
mechanisms by which sakuranetin reduced the lung al-
terations in this model, it is possible that at this time,
sakuranetin directly inhibited elastase activity, as has
been described by others [29]; this could have induced
slightly less lung injury and therefore reduced inflamma-
tion and remodeling. Although we have not evaluated
the effects of sakuranetin on elastase activity, this should
be considered a possibility. However, some authors have
shown by micro-CT chest imaging that airspace enlarge-
ment has already occurred by one hour after elastase in-
stillation [23], as discussed above. These data could
suggest that the animals already had some degree of
lung destruction when sakuranetin was administered.
In in vivo studies, it is difficult to exactly distinguish
the direct or indirect effects of a tested compound. In
experimental models of elastase-induced emphysema,
elastase directly destroys the elastic fibers and the ECM,
which in turn induces a repair process that involves
recruiting inflammatory cells to the local injury site and
regenerating the ECM components. Activated neutro-
phils release more elastase and generate reactive oxygen
and nitrogen species that create a proteolytic milieu.
Sakuranetin is a well-known antioxidant [43]; however, it
also has anti-inflammatory effects because it inhibits
NF-κB expression [16]. Therefore, we hypothesize that
sakuranetin functions preventively by reducing oxidative
stress and inhibiting NF-kB activation to reduce inflam-
mation, which consequently attenuates the degradation
of the alveolar septa. Furthermore, sakuranetin increased
the expression of TIMP-1, which inhibits the activity of
MMP-9, a metalloprotease that is involved in lung de-
struction. Although the exact effects should be further
evaluated, the direct and/or indirect effects of sakurane-
tin on inflammation reduction have considerable clinical
relevance.
Because the lung structure differs between humans
and animal models, the data provided here should be
interpreted carefully in terms of translating the effects to
humans. Furthermore, is important to note that this
emphysema model represents a mild form of the disease.
In experimental models of cigarette smoke-inducedemphysema, the inflammatory cell profile and the lung
function alterations are different because chronic bron-
chitis is established first. In models of elastase-induced
emphysema, the first alteration is alveolar tissue destruc-
tion. Finally, we did not detect any toxic effects of the
flavonoid treatment; studies conducted with Asteraceae
species did not show any hepatotoxic effects [44].Conclusion
In conclusion, we demonstrated that sakuranetin, a plant-
derived flavonoid compound, attenuated lung inflamma-
tion, lung destruction and lung remodeling in a model of
pulmonary emphysema. The inhibition of p65-NF-κB and
pro-inflammatory cytokine expression, the reduction in oxi-
dative stress responses and the improvement in the MMP/
TIMP imbalance may account for these observations.
Sakuranetin prevented the development of experimental
emphysema; thus, it may represent a novel pharmacological
tool that requires further investigation.
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